AstraZeneta's 12-week vaccination is still 76% effective and a new generation of vaccines will be introduced

As of 3 a.m. local time on February 5, the total number of confirmed cases in the UK was 3,892,459, with 20,634 new confirmed cases in one day and 915 new deaths in one day.
has slowed down compared to previous signs of virus transmission.
data Source: CDC WHO · ECDC UK Health Minister Matt Hancock said the AstraZeneca vaccine, which is a way out of the pandemic, was beginning to work slowly and slow the spread of the virus.
, However, Prime Minister Johnson warned that it was too early to talk about lifting the blockade and that the government would not agree to reopen schools in England by March 8.
on December 30 last year, The AstraZenecom vaccine was approved for emergency use by the UK regulator, the MHRA, in two standard doses, between four and 12 weeks.
in the UK will include the immediate first dose of the vaccine for high-risk groups and the delivery of a second dose after 12 weeks.
while the vaccine has shown to be effective against new coronavirus variants in the UK, with the emergence of variants in Brazil and South Africa, the research and development team is concerned about whether the vaccine is just as effective against other variants. the
vaccine's research and development team said it had begun work on a "second-generation" vaccine that would improve existing vaccines for new coronavirus variants, hoping to complete research and development by the autumn and get approval from the UK Medicines and Healthcare Products Authority (MHRA).
xinouzhou, Oxford University recently published on the Lancet website a new peer-reviewed study of a new crown vaccine developed with AstraZeneta showed that its new crown vaccine after a dose may have a "significant effect" on curbing the spread of the virus, with a 76 per cent effective rate for symptomatic infections within three months of a single injection, and an increase in efficacy if a second injection is delayed, supporting UK vaccine promotion policies.
comes after the UK decided to respond to the COVID-19 pandemic by extending the time between initial and enhanced injections to vaccinate as many people as possible as soon as possible to achieve group immunity.
Source bit.ly/3apMSyt Preprints with The Lancet, online February 1, 2021. The efficacy of single dose of an effective vaccine on the primary symptom COVID-19, based on the first and second dose intervals, A) SD/SD or LD/SD after the drug was given, B) SD/SD after the drug was given, C) LDSD after the efficacy of the vaccine collected from trials in the United Kingdom, Brazil and South Africa, 17 years of age between 18 and 55 years old Among 000 participants, a longer interval of the second dose of vaccine can improve the immune response, 12 weeks or more after the first dose, the second dose of vaccine effectiveness rate of 82.4%, while the first dose of less than 6 weeks after the second dose of vaccination is 54.9%, 56 years and older people with the longest interval of 6-8 weeks, so there is no 12 weeks after the efficacy of the population.
, Oxford University said the data showed that the vaccine reduced the spread of infection, with a 67 per cent reduction in positive swabs in the British group tested.
Pollard, lead researcher on the vaccine trial, said the data showed that a 12-week dose interval was "the best way to get a vaccine, and people can be protected 22 days after a single dose of the vaccine."
8-12 weeks between injections appears to be the focus of efficacy, according to the head of research at AstraZeneta, a U.S. drugmaker that has not been tested at such intervals.
but some independent researchers say it is difficult to draw a comprehensive conclusion from these results because of the limitations of the trial.
new study does not address concerns about the efficacy of giving the uk government the highest priority in its vaccine rollout for older people who lack data. the European Medicines Agency (EMA) said that although there was insufficient data to understand the effectiveness of the Oxford vaccine for older people, it was expected to be protective given the immune response seen in trials in that age group, so it was accepted that the vaccine could be used in older people, as was the case in the UK,
observer reported.
although the EMA recommends vaccination for all ages of adulthood, some EU countries do not recommend vaccination for older people.
germany has announced that vaccinations for people over 65 years of age are not recommended.
Italy's Drug Administration (AIFA) approved the vaccine last month for all adults, but recommended that groups over 55 be vaccinated against other varieties.
And the Swiss Drug Administration, which lights the vaccine directly red, said in a statement released on February 3rd that more information was needed on its safety, efficacy and quality, and that more data was needed from pharmaceutical bodies if they were willing to provide such data for evaluation by Swiss national authorities, which would issue emergency use authorizations in the shortest possible time.
It is worth mentioning that a few months ago, a private hospital group in Thailand submitted to the Thai Medicines Regulatory Authority an application for import registration of the New Crown Vaccine in China, but since then the application for the Oxford Vaccine in the United Kingdom has been applied for, and the New Crown Vaccine in China has not yet been approved.
Thailand's Drug Administration explained that whether it is the Chinese Vaccine or the Oxford Vaccine in the United Kingdom, our primary concern is the safety and effectiveness of the vaccine, which is not a simple business practice, first come, first 7 .00.
's new crown vaccine is not as effective in Brazil as expected, leading us to put a lot of pressure on public opinion on how to make a deal.
understands that AstraZene will continue to live up to its commitment to broad and equitable access to vaccines.
, more than 2 billion doses of vaccines have been agreed with the Alliance for Innovation in Epidemiology Prevention (CEPI), the Vaccine Alliance Gavi, the Indian Serum Institute (SII) and the Alliance for Inclusive Vaccines (IVA).
News Agency, February 5, British pharmaceutical giant AstraZeneta said on the 5th, has submitted to Japan's Ministry of Health, Labour and Industry for approval of the new crown vaccine, and the supply of 120 million doses, of which 90 million doses will be produced in China.
is the second company to apply for domestic vaccine approval, following Pfizer in the U.S., according to a report in the U.S.
Oranghy Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here